Diligence memo · auto-generated · as of July 2, 2026

Bryn Pharma, LLC

Bryn Pharma, LLC looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Bryn Pharma, LLC operates in Pharma, based in LEBANON.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Bryn Pharma, LLC has raised $127M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $44M on 2021-07-06.

Most recent recorded round closed around 2025-04-10.

Valuation (modeled)modeled

Provath models Bryn Pharma, LLC at approximately $31M (range $15M–$43M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.10× the median modeled value of Series C Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 15 mo ago; this sector typically re-raises about every 16 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 5.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 94% of Pharma peers (310 compared).

Modeled value ranks above 50% of those peers.

Closest niche peers: Click Therapeutics, Inc., Allay Therapeutics, Inc., Somite Therapeutics, Inc., Indapta Therapeutics Inc., Pheast Therapeutics, Inc..

Peoplefiled

23 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.